Malignant Melanoma Clinical Trial
Official title:
Test of Developed Interventions to Prevent Skin Cancer: a Randomized Study Targeting Danes Going on Vacation to Sunny Destinations With High UV Index
Verified date | July 2019 |
Source | Danish Cancer Society |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The aim of the study is to test a series of developed effective interventions targeting Danes going on vacation to sunny destinations to decrease sunburn by increasing use of shade, hats, protective clothing, and sunscreen to prevent skin cancer in the Danish population. It has been estimated that up to 90 % of all skin cancers could be avoided by behavioral changes. One of the main sources of UVR exposure in the Danish population is vacations to destinations with high UV index (UVI).
Status | Completed |
Enrollment | 1548 |
Est. completion date | January 11, 2019 |
Est. primary completion date | January 11, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 99 Years |
Eligibility |
Inclusion Criteria: - Travel for a vacation to a location with higher UVI than Denmark in the trial period (May-December 2018) - Access to a smartphone compatible with either iOS (version 7 or newer) or Google Android ( version 4.0 or newer) Exclusion Criteria: - Physically or mentally uncapable to complete the planned intervention routines |
Country | Name | City | State |
---|---|---|---|
Denmark | Danish Cancer Society | Copenhagen |
Lead Sponsor | Collaborator |
---|---|
Brian Køster |
Denmark,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Sunburn | Any erythema (selfdetermined by questionnaire which is sent within a week after travelling home) | Experienced during participants vacationperiod (1-3 weeks within may-dec 2018) | |
Secondary | Awareness of skin cancer risk | determined by questionnaire which is sent within a week after travelling home | Experienced during participants vacationperiod (1-3 weeks within may-dec 2018) | |
Secondary | Use of sunprotection;shade | determined by questionnaire which is sent within a week after travelling home | Experienced during participants vacationperiod (1-3 weeks within may-dec 2018) | |
Secondary | Use of sunprotection;clothes | Experienced during participants vacationperiod (1-3 weeks within may-dec 2018) | ||
Secondary | Use of sunprotection;hat | determined by questionnaire which is sent within a week after travelling home | Experienced during participants vacationperiod (1-3 weeks within may-dec 2018) | |
Secondary | Use of sunprotection;sunscreen | determined by questionnaire which is sent within a week after travelling home | Experienced during participants vacationperiod (1-3 weeks within may-dec 2018) | |
Secondary | Sunburn body site | determined by questionnaire which is sent within a week after travelling home; relation between relevance of sunprotection and sunburned area | Experienced during participants vacationperiod (1-3 weeks within may-dec 2018) | |
Secondary | Exposure in UV peak hours | determined by questionnaire which is sent within a week after travelling home | Experienced during participants vacationperiod (1-3 weeks within may-dec 2018) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04229277 -
Fast Track Diagnosis of Skin Cancer by Advanced Imaging
|
N/A | |
Completed |
NCT03653819 -
High Intensity Interval Training (HIIT) for Patients With Cancer-related Lymphedema in the Lower Limbs
|
N/A | |
Active, not recruiting |
NCT04074096 -
Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis
|
Phase 2 | |
Completed |
NCT02935790 -
Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab
|
Phase 1 | |
Recruiting |
NCT05478876 -
Carbon Ion Radiation Therapy in the Treatment of Mucous Melanomas of the Female Lower Genital Tract
|
N/A | |
Completed |
NCT01211262 -
Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma
|
Phase 1 | |
Recruiting |
NCT03649529 -
Treatment of Malignant Melanoma With GPA-TriMAR-T Cell Therapy
|
Early Phase 1 | |
Completed |
NCT03278665 -
4SC-202 in Combination With Pembrolizumab in Patients Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy
|
Phase 1/Phase 2 | |
Completed |
NCT04452214 -
A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors
|
Phase 1 | |
Terminated |
NCT02709889 -
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT01455259 -
Phase I/IIa AdCD40L Immunogene Therapy for Malignant Melanoma and Other Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT00978913 -
Transfected Dendritic Cell Based Therapy for Patients With Breast Cancer or Malignant Melanoma
|
Phase 1 | |
Completed |
NCT00232726 -
Clinical Study of Previously Untreated Patients With Malignant Melanoma
|
Phase 2 | |
Completed |
NCT00350597 -
GM-CSF as Adjuvant Therapy of Melanoma
|
Phase 2 | |
Completed |
NCT00336986 -
Efficacy Study of IL-21 to Treat Metastatic Melanoma
|
Phase 2 | |
Completed |
NCT02523313 -
Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NED
|
Phase 2 | |
Completed |
NCT03545334 -
Lymph Node Identification in Skin Malignancy Using ICG Transcutaneously Study
|
N/A | |
Completed |
NCT04253574 -
Comparison of PET/CT and Ultrasound in Staging of Malignant Melanoma
|
||
Completed |
NCT00179608 -
Study of the Combination of Lenalidomide and DTIC (Dacarbazine) in Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic Chemotherapy
|
Phase 1 | |
Terminated |
NCT00104884 -
FR901228 in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma
|
Phase 2 |